Cerevel Therapeutics Holdings Inc (CERE)
40.78
+0.14
(+0.34%)
USD |
NASDAQ |
May 31, 16:00
40.74
-0.04
(-0.10%)
Pre-Market: 20:00
Cerevel Therapeutics Holdings Cash from Financing (Quarterly): 4.475M for March 31, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 4.475M |
| December 31, 2023 | 508.37M |
| September 30, 2023 | 1.195M |
| June 30, 2023 | 37.61M |
| March 31, 2023 | 1.435M |
| December 31, 2022 | 2.131M |
| September 30, 2022 | 578.64M |
| June 30, 2022 | 39.82M |
| March 31, 2022 | 2.603M |
| Date | Value |
|---|---|
| December 31, 2021 | 2.316M |
| September 30, 2021 | 387.58M |
| June 30, 2021 | 32.96M |
| March 31, 2021 | 0.742M |
| December 31, 2020 | 420.07M |
| September 30, 2020 | 22.29M |
| June 30, 2020 | -1.524M |
| March 31, 2020 | 0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-1.524M
Minimum
Jun 2020
578.64M
Maximum
Sep 2022
120.04M
Average
4.475M
Median
Mar 2024
Cash from Financing (Quarterly) Benchmarks
| AbbVie Inc | 10.82B |
| Bristol-Myers Squibb Co | 14.64B |
| Madrigal Pharmaceuticals Inc | 573.71M |
| Viking Therapeutics Inc | 606.04M |
| Karuna Therapeutics Inc (DELISTED) | 19.87M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -119.67M |
| Cash from Investing (Quarterly) | 19.16M |
| Free Cash Flow | -370.79M |
| Free Cash Flow Per Share (Quarterly) | -0.6604 |
| Free Cash Flow Yield | -5.40% |